Carta Healthcare, whose software program platform applies AI to structured and unstructured information to lower the time and prices for information abstraction, has acquired Realyze Intelligence, which applies comparable know-how to oncology.
Based in 2019, San Francisco-based Carta Healthcare mentioned it applies each synthetic intelligence and skilled medical information abstractors to serve a variety of well being methods nationwide, from standalone group hospitals to massive tutorial medical facilities. It lists Mass Normal Brigham, CommonSpirit and Grady as amongst its well being system clients.
Realyze Intelligence was fashioned in 2020 as a portfolio firm of UPMC Enterprises, the innovation, commercialization and enterprise capital arm of UPMC. Its software program analyzes structured and unstructured information in digital well being information to determine best sufferers for medical trials and different analysis research. The corporate says its clinician-trained AI can assemble applicable cohorts in seconds as a substitute of the everyday hours or days the method consumes when carried out manually. Realyze Intelligence is utilized by most cancers facilities and is a part of the Memorial Sloan Kettering Most cancers Middle Innovation Hub. The CancerX Accelerator Program additionally chosen Realyze Intelligence as a part of its inaugural program earlier this yr.
Phrases of the acquisition weren’t disclosed.
A Realyze Intelligence evaluation discovered that by utilizing the software program, UPMC Hillman Most cancers Middle noticed seven instances extra sufferers matched to trials and twice as many enrolled, in comparison with the identical timeframe with out utilizing the software program.
“We consider information is the only most essential ingredient to enhance healthcare,” mentioned Brent Dover, CEO of Carta Healthcare, in a press release. “From medical trials to medical registries, clinicians face insurmountable quantities of information ripe with invaluable data to enhance care practices and affected person outcomes. We’re impressed by Realyze Intelligence’s shared means to make use of clinician-trained AI and a human-in-the-loop strategy to maximise insights from medical information, for medical trials and most cancers registries.”
“Well being methods and pharmaceutical firms make investments billions yearly to determine and enroll sufferers for medical trials—a course of that isn’t solely pricey however labor-intensive and time-consuming,” mentioned Aaron Brauser, founder and CEO of Realyze Intelligence, in a press release. “Excessive-quality, well timed information is important for precisely figuring out eligible sufferers, but a lot of it stays trapped in EHRs and different methods. We’re excited to revolutionize medical trial matching and reuse the information to reinforce analysis, optimize care pathways and enhance affected person outcomes with Carta Healthcare.”
